NO Time for Old Drugs
- 5 Downloads
The ubiquitous physiological effects of the nitric oxide (NO) messenger molecule mean that NO-based therapeutics are potentially useful in most areas of medicine. The French company NicOx is pursuing a unique approach to this technology by combining NO-releasing compounds with established pharmaceuticals. The dual mechanism of such agents is hoped to offer significant therapeutic advantages. NicOx is mainly focused on applying this technology platform to cardiovascular disease, inflammatory disorders and pain, but also has programs in development for neurodegenerative, respiratory, liver and dermatological diseases.
Underlining the potential of the NicOx approach are collaborations with the pharmaceutical giants Pfizer and Merck & Co., as well as smaller pharma and biotech companies. NicOx currently has seven compounds in clinical trials, with its lead candidates being a naproxen derivative scheduled to enter phase III trials soon for osteoarthritis (HCT-3012), and an...